Search | Clinical Trials Finder

Conditions: Lichen Planopilaris, Frontal Fibrosing Alopecia
Interventions: Low-Dose Naltrexone; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hypercholesterolemia
Interventions: Enlicitide, Ezetimibe, Bempedoic Acid, Placebo for Enlicitide, Placebo for Ezetimibe, Placebo for Bempedoic Acid; Drug · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 7
States / cities: Lincoln, California • Flossmoor, Illinois • Louisville, Kentucky + 4 more

Conditions: Solid Tumors, Breast Cancer, Cowden Syndrome
Interventions: BGT226; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 4
States / cities: Boston, Massachusetts • Las Vegas, Nevada • San Antonio, Texas

Conditions: Atrial Fibrillation
Interventions: Apixaban, Parenteral heparin and/or oral Vitamin K antagonist; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 63
States / cities: Birmingham, Alabama • Avondale, Arizona • Chula Vista, California + 32 more

Conditions: Candidiasis, HIV Infections
Interventions: Not listed
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Interventions: Clofarabine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Heavy Menstrual Bleeding, Uterine Fibroids
Interventions: Not listed
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 51 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Schizophrenia, Pediatric
Interventions: Lumateperone 42 mg, Lumateperone 28 mg; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Hollywood, Florida • Atlanta, Georgia • Decatur, Georgia

Conditions: Bipolar Disorder
Interventions: Ziprasidone oral capsules, placebo oral capsules; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 50
States / cities: Scottsdale, Arizona • Orange, California • San Diego, California + 41 more

Conditions: Multiple Myeloma
Interventions: Ixazomib, Lenalidomide, Dexamethasone; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 20
States / cities: Berkeley, California • Duarte, California • Stanford, California + 15 more

Conditions: Xerostomia
Interventions: HYDRAL Oral Rinse, BIOTENE® Oral Rinse, Placebo Oral Rinse; Device
Lead sponsor: Sunstar Americas; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer, Oral Cavity Cancer, Larynx Cancer
Interventions: ENDURE; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 532 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: St Louis, Missouri • Durham, North Carolina • Charleston, South Carolina + 1 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, Fasiglifam; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 55
States / cities: Dothan, Alabama • Muscle Shoals, Alabama • Goodyear, Arizona + 52 more

Conditions: Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression
Interventions: Zanidatamab; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 17
States / cities: Prescott, Arizona • Littleton, Colorado • Fort Myers, Florida + 14 more

Conditions: HIV Infections
Interventions: GSK3640254, Placebo, Moxifloxacin; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Migraine
Interventions: topical intraoral ketoprofen gel, Placebo Gel; Drug · Other
Lead sponsor: Behar, Caren, M.D.; Individual
Eligibility: 18 Years to 75 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Valhalla, New York

Conditions: Pruritus, Notalgia Paresthetica
Interventions: difelikefalin 2.0 mg, Placebo; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 26
States / cities: Fort Smith, Arkansas • Hot Springs, Arkansas • Rogers, Arkansas + 23 more

Conditions: Sjögren's Syndrome
Interventions: Deucravacitinib, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 774 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 28
States / cities: Fullerton, California • La Palma, California • San Francisco, California + 25 more

Conditions: Dilated Cardiomyopathy
Interventions: AZD0233, AZD0233 Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Glendale, California

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Dexamethasone, Montelukast, Methotrexate, Amivantamab, Lazertinib; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Fountain Valley, California • Fairfax, Virginia • Renton, Washington

Conditions: Anemia, Iron Deficiency, Heavy Menstrual Bleeding
Interventions: Ferumoxytol, Ferrous Sulfate; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Larynx, Lip, Oral Cancer, Digestive Organs--Diseases
Interventions: Durvalumab, Intensity Modulated Radiotherapy Treatments; Drug · Radiation
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 3
States / cities: Birmingham, Alabama • Chapel Hill, North Carolina • Charleston, South Carolina

Conditions: Systemic Sclerosis, Calcinosis
Interventions: Oral treprostinil; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Myelodysplastic Syndrome
Interventions: ON 01910.Na; Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Tampa, Florida • New York, New York

Search by objective public record fields.

Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia

A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)

A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer

Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

Incidence of Oral Candidiasis, Prevalence of C. Dubliniensis in HIV Patients and In-vitro Azole Susceptibility

Oral Clofarabine Study in Patients With Myelodysplastic Syndrome

A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of Bleeding in Adult Participants With Heavy Menstrual Bleeding Due to Uterine Fibroids Taking Oral Oriahnn Capsules

Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder

Safety and Efficacy of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)

Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma

Clinical Evaluation of Oral Rinse for Xerostomia

Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy

Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of Moxifloxacin

Topical Intra-Oral Ketoprofen for Migraine Prevention

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)

A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

IV Iron vs Oral Iron for Treatment of Anemia in Women With Abnormal Uterine Bleeding

Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN

Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis

Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome